FOX BUSINESS NETWORK’S CHARLIE GASPARINO REPORTS VALEANT PHARAMACEUTICALS IS “ACTIVELY DISCUSSING” SELLING ITS BAUSCH AND LOMB UNIT
FOX Business Network’s (FBN) Charlie Gasparino reports Valeant Pharmaceuticals is “actively discussing” selling its Bausch and Lomb unit.
On whether Valeant Pharmaceuticals will sell its Bausch and Lomb:
This year has been a record-breaking year for initial public offerings with companies going public via SPAC mergers, direct listings and standard IPOS. At Techlive this week, Jack Cassel of Nasdaq and A.J. Murphy of Standard Industries joined Willem Marx of The Wall Street Journal and Barron's Group to talk about companies and trends in Read More
“This is what we have from sources, investment bankers that are dealing with in this issue right now, that Valeant is eyeing asset sales to pay down some of its debt. It’s got $32 billion in debt and one of the assets we hear that they are actively discussing and this is a pretty big deal if this ever comes to fruition is Bausch and Lomb unit. It bought Bausch and Lomb I believe in 2013, bankers are telling the FOX Business Network that inside they are actively discussing a potential sale of that to pay down some of that debt. How much could they get it for? Well they bought it for $9 billion in 2013. I mean I’ve seen estimates range from about $20 – $30 billion you could get for this.”